Non-valvular Atrial Fibrillation (NVAF)
Conditions
Brief summary
The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.
Interventions
DRUGApixaban
Sponsors
Bristol-Myers Squibb
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
Exclusion criteria
* Subjects who received Apixaban as part of a clinical trial * Subjects who received Apixaban for any indication other than local approval (ie, to reduce the risk of stroke and systemic embolism in patients with NVAF)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the reporting rate of on-treatment adverse events (AEs) by the treating physicians | Up to 24 month study period |
| Identify, describe, and report any suspected AEs that occur while on treatment with Apixaban or preventing stroke and systemic embolism in patients with NVAF | Up to 24 months |
Countries
Mexico
Outcome results
None listed